Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04283539 · ClinicalTrials.gov registry record
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 255
- Enrollment target
NCT04283539 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 255 participants.
The verdict
NCT04283539 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
Study Summary
This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.
Interventions
- DRUG systemic corticosteroid or biologic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2020-09-23 |
| Est. Completion | 2026-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04283539
The ClinicalTrials.gov registry entry for NCT04283539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which systemic corticosteroid or biologic is the first listed.
NCT04283539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04283539 about?
NCT04283539 is a clinical study titled "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy". This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune r...
What is the current status of trial NCT04283539?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2020-09-23. Estimated completion is 2026-02-28.
What interventions are being tested in trial NCT04283539?
The interventions under investigation include: systemic corticosteroid or biologic (DRUG).
Who is sponsoring clinical trial NCT04283539?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.